Diagnosis of
oncological diseases
Diagnosing a disease involves multiple aspects and includes a clinical examination as well as various imaging procedures using advanced technologies. These range from initial X-rays or ultrasound scans to more detailed examinations with computed tomography (CT scans), magnetic resonance imaging (MRI), or positron emission tomography (PET), along with numerous laboratory tests or tissue sample analyses using special microscopic techniques - all aimed at confirming the diagnosis.
A major breakthrough in cancer diagnosis and treatment is the use of tests for the presence of circulating tumor cells, along with the examination of their structure and potency, as well as their sensitivity to all officially recognized drugs and procedures used in the fight against cancer.
Biomed Aid in collaboration with the RGCC group offers general tests for the detection of circulating tumor cells.
These tests give the therapist the opportunity to individually develop a proposal for a therapeutic strategy for each patient, which is known with certainty to give the best possible results.
TESTS
BIOMED AID in cooperation with R.G.C.C. Laboratories offers general tests for the detection of CTC’s (circulating Tumor Cells), as well as tests for following up the specific types of cancer, including breast, colon, prostate, malignant melanoma and sarcoma…
These tests allow:
1. Detecting early signs of cancer in development.
2. Help in monitoring existing cancers.
3. Creating an individual profile, which drugs for cancer treatment, therapeutic methods and which natural substances can be used to achieve the best treatment outcome.
Percentage sensitivity testing to drugs and therapies for cancer treatment, such as cytostatics, radiotherapy, oncothermia, monoclonal antibodies, small molecular wight agents, supplements... is also done.
Onconomics RGCC
Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.
The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analyzed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of these two testing methods provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer.
The test can be used for all types of cancer. The sample size is 15-25 ml. peripheral whole blood.
The analysis period is 10-12 days.
The test is clinically validated and highly accurate (≈91%)
Onconomics Plus RGCC
Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies, and natural treatments on the cancer cells in an individual patient.
During the test, a sample of blood or tissue is analyzed to test how effective specific therapies and treatments are at suppressing cancer.
Together, the results of the extensive tests provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used by clinicians to design personalized and targeted cancer therapies with the highest chances of success.
The test can be used for all types of cancer. The sample size is 15-25 ml. peripheral whole blood.
The analysis period is 10-12 days.
The test is clinically validated and highly accurate (≈91%)
Onco-D-Clare
Onco-D-Clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear.
Peripheral blood mononuclear cells are isolated from blood samples, and gene expression analysis is performed in more than 90 genes. Their expression profile is then used for the classification of the sample as cancerous or healthy.
The Onco-D-Clare test provides individuals with essential information to help them make better-informed decisions about future health and well-being.
This test can be used for all types of cancer, except brain cancers and CNS (Central Nervous System) cancers. The sample size is 5-8 ml. peripheral whole blood.
The analysis period is 7-10 days.
The test is clinically validated and highly accurate (≈93%)
RGCC CAMBISeq
RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.
The CAMBISeq® – or cancer analysis, mutational burden, and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapies.
RGCC CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.
The test can be used for all types of cancer. The sample size is 10-15 ml. peripheral whole blood. Fresh tissue Minimum 400 mg. FFPE Minimum 100 mg. (or 1 block).
The analysis period is 3-4 weeks.
The test is clinically validated and highly accurate (≈93%)
Onconomics Extracts
Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plant extracts are at attacking circulating cancer cells (CTCs).
Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalized analysis of the most effective natural treatments that patients can use to treat their cancer, alongside conventional therapies.
The test can be used for all types of cancer. The sample size is 15-25 ml. peripheral whole blood.
The analysis period is 10-12 days.
The test is clinically validated and highly accurate (≈92%)
Onconomics Extracts+
Onconomics Extracts+ provides highly detailed and accurate information about how effective specific natural substances and plant extracts are, as anticancer agents as well as the gene expression profile of genes, associated with fundamental biological processes. This includes processes such as angiogenesis, cell cycle regulation, self-repair, metastasis, apoptosis, proliferation etc. Circulating tumor cells are isolated from a peripheral blood sample and then used for different assays. The results provide a comprehensive and highly personalized analysis of the most effective natural treatments that patients can use to treat their cancer, alongside conventional therapies.
Natural substances and extracts that are tested are divided into Class-I (Cytotoxic agents), Class-II (Immunostimulants / immunomodulators), and Class-III (PK inhibitors).
The test can be used for all types of cancer. The sample size is 15-25 ml. peripheral whole blood.
The analysis period is 10-12 days.
The test is clinically validated and highly accurate (≈92%)
Metastat RGCC
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumor is likely to develop and its potential location.
During the test, we analyze a sample of a patient’s blood in our state-of-the-art laboratory to analyze, identify and measure circulating tumor cells (CTCs).
Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumors and improve personalized cancer treatments.
The test can be used for all types of cancer. The sample size is 10-15 ml. peripheral whole blood.
The analysis period is 10-12 days.
The test is clinically validated and highly accurate (≈93%)
ChemoSNiP
ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyze how a patient’s body will respond to a specific drug.
ChemoSNiP analyses a blood sample to identify single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs, and other agents.
ChemoSNiP provides clinicians with a powerful insight into which drugs are most effective at treating cancer. The results provide a personalized analysis that can be used to provide the most effective combination of drugs and treatments available.
The test can be used for all types of cancer. The sample size is 10-15 ml. peripheral whole blood.
The analysis period is 10-12 days.
The test is clinically validated and highly accurate (≈93%)
Immune-Frame
Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off.
The results of Immune-Frame can be used to analyze the status of a patient’s immune system, and to provide ongoing information about their health status. This information can be used by clinicians to advise on potential health risks a patient may face, and how these can be minimized.
The test can be used for all types of cancer. The sample size is 10-15 ml. peripheral whole blood.
The analysis period is 7-10 days.
The test is clinically validated and highly accurate (≈92%)
InViomma Plus
InVyomma Plus focuses on gut microbiome profiling, including analysis of short-chain fatty acids, and how they are associated with cancer.
It has been discovered that the microbiome is closely related to the occurrence and development of a variety of cancer types in the epithelial barrier and sterile tissues. Symbiotic ecosystems that inhabit the gut or other mucosa perform a role in both local and distal carcinogenesis.
On the one hand, the microbiome can provide toxic metabolites or carcinogenic products directly as cancer-transforming agents. Moreover, it can indirectly play a role in promoting cancer by the induction of inflammation or immunosuppression and can modulate the efficacy and toxicity of cancer therapy.
The InVyomma Plus test provides clinicians with essential information to help them make better-informed decisions about future treatment, health, and well-being.
InVyomma Plus requires 4 stool Collection Tubes, 2 for the gut microbiome profiling, and 2 for short-chain fatty acids analysis. The experimental/analysis period is approximately 2-3 weeks, and the results are ready in 2-4 weeks after the sample’s arrival in the laboratory facilities.
The test can be used for all types of cancer.
The analysis period is 3-4 weeks.
The test is clinically validated and highly accurate (≈92%)
ArraiCGH RGCC
The array comparative genomic hybridization (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.
During the test, scientists use a technique called array comparative genomic hybridization to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumor. aCGH RGCC can help clinicians to understand more about a patient’s genes, giving them a powerful tool in the fight against cancer.
The test can be used for all types of cancer. The sample size is 10-15 ml. peripheral whole blood.
The analysis period is about 4 weeks.
The test is clinically validated and highly accurate (≈93%)
MONITORING TESTS
Oncocount RGCC
Oncocount RGCC detects the presence of circulating tumor cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning.
The test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount RGCC test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).
The test can be used for all types of cancer. The sample size is 10-15 ml. peripheral whole blood.
The analysis period is 7-10 days.
The test is clinically validated and highly accurate (≈93%)
Oncotrail RGCC
Oncotrail RGCC provides crucial information on the presence of circulating tumor cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer: breast, colon, prostate, lung, melanoma, GI cancer and sarcoma.
During the test, a sample of blood is analyzed to identify the presence and concentration of CTC and their immunophenotype.
Oncotrail RGCC is not used as a primary diagnostic test to confirm a cancer diagnosis, but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.
The sample size is 10-15 ml. peripheral whole blood.
The analysis period is 7-10 days.
The test is clinically validated and highly accurate (≈93%)
Oncotrace RGCC
Oncotrace RGCC is used to identify a primary tumor in a patient and to provide guidance about disease progression and future prognosis.
During the test, a sample of blood is analyzed to identify the presence and concentration of circulating tumor cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration, and their specific type (immunophenotype).
The results of the test enable clinicians to identify the origin of a tumor where this is unknown and to provide information on the development of cancer and the prognosis.
The test can be used for all types of cancer.
The sample size is 10-15 ml. peripheral whole blood.
The analysis period is 7-10 days.
The test is clinically validated and highly accurate (≈93%)
